EMA multi-stakeholder workshop on supporting innovation in cardiovascular medicines and medical devices in the EU

Workshop on supporting innovation in cardiovascular medicines and medical devices in the EU.

• Date:
  Wednesday, 01 July 2026 , 13:00 - 19:00 Amsterdam time (CEST)
  Thursday, 02 July 2026 , 09:00 - 16:00 Amsterdam time (CEST)
• Location:
  Online
  European Medicines Agency, Amsterdam, the Netherlands
  Live broadcast

Event summary

This multi-stakeholder workshop covers interdisciplinary discussions addressing a range of important topics including clinical gaps, development challenges and regulatory strategies, advancing prevention and treatment in cardiovascular (CV) diseases and their overlapping areas including diabetes, obesity, lipid lowering and renal aspects. The role of real-world data as well as digitalisation and AI in CV innovation is also discussed. The participants include patients, healthcare professionals, academia, regulators, and industry.

The overall objective of the workshop is to enhance understanding among stakeholders on the interplay of regulation and innovation in CV medicines and medical devices. 

Video recording is published after the event. 

Documents

Agenda - EMA multi-stakeholder workshop on supporting innovation in cardiovascular medicines and medical devices in the EU

Draft

Presentation - Lived experience in unmet need (M. Holler)

Presentation - The safe hearts plan (Y. Azzopardi)

Presentation - Clinical research: opportunties and challenges (T. Lüscher)

Presentation - Recent (regulatory) developments in medicines for cardiovascular indications (A. Irs)

Presentation - Clinical imperatives for implementing regulatory science for medical devices (A. Fraser)

Presentation - Global collaboration in cardiovascular medicine development (M. Inoue)

Presentation - Cardiometabolic diseases: tackling the unmet need in cardiovascular risk reduction (J. Nabais)

Presentation - Cardiometabolic diseases: Tackling the unmet need in CV risk reduction (F. Giorgino)

Presentation - Adiposity: The gateway to cardiometabolic diseases (L. Fábryová)

Presentation - Challenges and opportunities in medicines and medical devices development (S. Dias)

Presentation - Challenges and opportunities in medicines development (A. Baczynska)

Presentation - Emerging and innovative therapies - state of play and key questions (O. Vedin)

Presentation - Emerging and innovative devices - state of play and key questions (J. Russo)

Presentation - Experience gained and lessons learned from recent and ongoing initiatives (A. Segec)

Presentation - Fostering innovation in cardiovascular diseases with digitalisationand AI (K. Azer)

Presentation - AI in cardiovascular care (F. Asselbergs)

Presentation - Artificial intelligence for drug development in cardiovascular medicine (C. Mittman)

Presentation - AI and digital technologies transforming cardiovascular device in novation (S. Zenker)